Curated News
By: NewsRamp Editorial Staff
February 18, 2026

LIXTE Appoints CEO for European Proton Therapy Subsidiary

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • LIXTE appoints Sidney Braun to lead Liora Technologies Europe, leveraging his acquisition expertise to scale the LiGHT proton therapy system and pursue recurring revenue in cancer radiotherapy.
  • LIXTE's appointment of Sidney Braun as CEO of Liora Technologies Europe supports scaling the LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment.
  • LIXTE's leadership appointment aims to advance proton therapy technology, potentially improving cancer treatment outcomes and making tomorrow better for patients through enhanced radiotherapy options.
  • LIXTE taps Sidney Braun, who facilitated their 2025 acquisition of Liora's assets, to lead advancement of the LiGHT System proton therapy platform in Europe.

Impact - Why it Matters

This news matters because it represents a significant development in cancer treatment innovation that could directly impact patient outcomes. LIXTE's dual approach—combining pharmaceutical development with advanced radiotherapy technology—addresses two critical fronts in oncology: systemic drug therapies and localized tumor treatment. The LiGHT System's proton therapy platform offers potentially more precise radiation delivery with fewer side effects than traditional methods, while LB-100's novel mechanism could enhance existing cancer treatments. For patients, this means potentially more effective, less toxic treatment options in the future. For the healthcare industry, it demonstrates how companies are integrating multiple therapeutic modalities to create more comprehensive cancer care solutions. The European expansion also suggests these technologies may become more widely available internationally.

Summary

LIXTE Biotechnology Holdings, a clinical-stage pharmaceutical company trading on NASDAQ as LIXT, has announced a strategic leadership appointment to advance its cancer treatment technologies. The company has named Sidney Braun as Chief Executive Officer of its European subsidiary, Liora Technologies Europe Ltd., following LIXTE's acquisition of Liora's assets in November 2025. Braun brings over two decades of healthcare operational and strategic advisory experience to this role, where he will lead the development of Liora's innovative LiGHT System—an electronically controlled proton therapy platform designed to enhance tumor treatment precision. This appointment aligns with LIXTE's broader strategy to scale this technology and establish a recurring revenue model within the radiotherapy segment of cancer care, marking a significant step in expanding their therapeutic portfolio beyond pharmaceutical development.

Beyond this leadership move, LIXTE Biotechnology is making waves in oncology with its pioneering approach to cancer treatment. The company's lead clinical compound, LB-100, represents a first-in-class PP2A inhibitor that has demonstrated both tolerability and anti-cancer activity in patients. This drug is part of what LIXTE terms "activation lethality"—an entirely new field of cancer biology that could potentially enhance the effectiveness of existing chemotherapies and immunotherapies. With proof-of-concept clinical trials currently underway for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, and a comprehensive patent portfolio protecting their innovations, LIXTE is positioning itself at the forefront of next-generation cancer therapies. For those interested in learning more about these developments, additional information can be found on the company's official website at www.lixte.com, and the full press release is available through the InvestorBrandNetwork at https://ibn.fm/9kbfE.

The broader context of this announcement reveals LIXTE's dual-track approach to transforming cancer care. While the company continues to advance its pharmaceutical pipeline with LB-100, the acquisition of Liora Technologies and the appointment of Braun to lead its European subsidiary demonstrates a strategic expansion into medical technology. This combination of pharmaceutical innovation and advanced radiotherapy technology creates a more comprehensive approach to cancer treatment that could potentially address multiple aspects of patient care. As with all forward-looking statements in the healthcare sector, investors and stakeholders should consider the inherent risks and uncertainties outlined in the company's SEC filings, but the current developments suggest LIXTE is building a multifaceted platform to combat cancer through both drug development and technological innovation.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LIXTE Appoints CEO for European Proton Therapy Subsidiary

blockchain registration record for this content.